Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 15/20 | 0.52 |
| ▸ | CA1 | P00915 | 15/20 | 0.52 |
| ▸ | CA2 | P00918 | 15/20 | 0.52 |
| ▸ | CA4 | P22748 | 15/20 | 0.52 |
| ▸ | CA7 | P43166 | 15/20 | 0.52 |
| ▸ | CA9 | Q16790 | 15/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | CCNC | P24863 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387371 | 1.00 | CA12 (0.52) | CA12CA1CA2CA4CA7 | |
| SCHEMBL22499821 | 0.84 | SYK (0.51) | CA12CA1CA2CA4CA7 | |
| SCHEMBL18890135 | 0.83 | GLS (0.51) | CA12CA1CA2CA4CA7 | |
| SCHEMBL18890179 | 0.83 | GLS (0.53) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4782081 | 0.81 | TRPV1 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL18920480 | 0.81 | LMNA (0.60) | CA12CA1CA2CA4CA7 | |
| SCHEMBL15379128 | 0.81 | LMNA (0.60) | CA12CA1CA2CA4CA7 | |
| SCHEMBL23387271 | 0.80 | CCNC (0.63) | CA12CA1CA2CA4CA7 | |
| SCHEMBL23387323 | 0.80 | CCNC (0.63) | CA12CA1CA2CA4CA7 | |
| SCHEMBL23387275 | 0.80 | CCNC (0.63) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | CA12 2261/4885CA1 922/4885CA2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.